March 27 (Reuters) - Novocure's (NVCR.O), opens new tab therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of lung cancer, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback